830 Winter Street
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems to re-balance immunity in severe autoimmune and inflammatory diseases. Q32 Bio’s lead programs, focused on the IL-7R pathway and complement system, address immune dysregulation to help patients take back control of their lives.
The first-in-human trial for the company’s most advanced program, ADX-914, a fully human anti-IL-7R antibody, is designed to evaluate safety and tolerability and demonstrate proof-of-mechanism. IL-7R has been genetically and biologically validated to drive several T cell-mediated pathological processes in numerous autoimmune diseases.
Q32 Bio’s lead program for innate immunity, ADX-097, is based on a pioneering approach enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics.
14 articles with Q32 Bio
Q32 Bio Presents Preclinical Data Highlighting the Design and Characterization of Lead Program for Innate Immunity, ADX-097, at the 28th International Complement Virtual Workshop 2021
Q32 Bio today announced preclinical data for the Company's lead program for innate immunity, ADX-097.
Q32 Bio to Present Preclinical Data on Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that it will present preclinical data supporting the Company's lead program for innate immunity, ADX-097, during an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2021, taking place virtually from November 4 to 7, 2021.
8/6/2021Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers.
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, announced the appointment of Kathy LaPorte to its Board of Directors.
7/9/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, announced the appointment of Adam Cutler as Chief Financial Officer.
Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of Jason Campagna , M.D., Ph.D. as Chief Medical Officer. Dr. Campagna brings more than 15 years of biotech and pharmaceutical experience to the Q32 Bio executive team
It didn’t take long for Jason Campagna to find a new role after departing Intercept Pharmaceuticals last month. Campagna will take on the role of chief medical officer for Q32 Bio.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of industry leader Mark Iwicki as Chairman of its Board of Directors
Q32 Bio rakes in $60 million Series B as they dose their first patient in IL-7R antibody trial.
Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis
Q32 Bio, a biotechnology company developing biologic therapeutics to restore healthy immune regulation, today announced the completion of a $60 million Series B financing co-led by OrbiMed Advisors and Acorn Bioventures.
Proprietary tissue-targeted complement platform and best-in-class IL-7R antibody technology to treat patients with severe autoimmune and inflammatory disease; clinical trials begin in 2020
With $46 million in Series A financing, Cambridge, Mass.-based Q32 Bio, with a focus on healthy immune regulation, has emerged onto the scene with plans to enter its lead asset into the clinic later this year.